United States - English - NLM (National Library of Medicine)

wyeth pharmaceuticals llc, a subsidiary of pfizer inc. - estrogens, conjugated (unii: iu5qr144qx) (estrogens, conjugated - unii:iu5qr144qx) - estrogens, conjugated 0.45 mg - limitation of use when prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, topical vaginal products should be considered. limitation of use when prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medication should be carefully considered premarin therapy is contraindicated in individuals with any of the following conditions: premarin should not be used during pregnancy [see contraindications (4)] . there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins as an oral contraceptive inadvertently during early pregnancy. premarin should not be used during lactation. estrogen administration to nursing women has been shown to decrease the quantity and quality of the breast milk. detectable amounts of estrogens have been identified in the breast milk of mothers receiving estrogen-alone therapy. caution should be exercised when premarin is administered to a nursing woman. estrogen therapy has been used for the induction of puberty in adolescents with some forms of pubertal delay. safety and effectiveness in pediatric patients have not otherwise been established. large and repeated doses of estrogen over an extended time period have been shown to accelerate epiphyseal closure, which could result in short stature if treatment is initiated before the completion of physiologic puberty in normally developing children. if estrogen is administered to patients whose bone growth is not complete, periodic monitoring of bone maturation and effects on epiphyseal centers is recommended during estrogen administration. estrogen treatment of prepubertal girls also induces premature breast development and vaginal cornification, and may induce vaginal bleeding. in boys, estrogen treatment may modify the normal pubertal process and induce gynecomastia. there have not been sufficient numbers of geriatric patients involved in studies utilizing premarin to determine whether those over 65 years of age differ from younger subjects in their response to premarin. the women's health initiative study in the whi estrogen-alone substudy (daily ce 0.625 mg-alone versus placebo), there was a higher relative risk of stroke in women greater than 65 years of age [see clinical studies (14.5)] . in the whi estrogen plus progestin substudy (daily ce [0.625 mg] plus mpa [2.5 mg]), there was a higher relative risk of nonfatal stroke and invasive breast cancer in women greater than 65 years of age [see clinical studies (14.5)] . the women's health initiative memory study in the whims ancillary studies of postmenopausal women 65 to 79 years of age, there was an increased risk of developing probable dementia in women receiving estrogen-alone or estrogen plus progestin when compared to placebo [see warnings and precautions (5.3), and clinical studies (14.6)] . since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women8 [see warnings and precautions (5.3), and clinical studies (14.6)]. the effect of renal impairment on the pharmacokinetics of premarin has not been studied. the effect of hepatic impairment on the pharmacokinetics of premarin has not been studied.

New Zealand - English - Medsafe (Medicines Safety Authority)

wyeth consumer healthcare a division of wyeth (nz) limited - cyanocobalamin 2.5 mg/ml; ferric pyrophosphate 12.5 mg/ml; lysine 30 mg/ml; pyridoxine hydrochloride 0.5 mg/ml; thiamine hydrochloride 1 mg/ml - syrup - 200 ml - active: cyanocobalamin 2.5 mg/ml ferric pyrophosphate 12.5 mg/ml lysine 30 mg/ml pyridoxine hydrochloride 0.5 mg/ml thiamine hydrochloride 1 mg/ml excipient: ethanol sodium benzoate sorbic acid sorbitol

New Zealand - English - Medsafe (Medicines Safety Authority)

wyeth consumer healthcare a division of wyeth (nz) limited - ibuprofen 200mg;   - liquid filled capsule - 200 mg - active: ibuprofen 200mg   excipient: fast green fcf gelatin glycerol macrogol 400 povidone propylene glycol purified water sodium hydroxide sorbitol

New Zealand - English - Medsafe (Medicines Safety Authority)

wyeth consumer healthcare a division of wyeth (nz) limited - ibuprofen 20 mg/ml;   - oral suspension - 100 mg/5ml - active: ibuprofen 20 mg/ml   excipient: allura red ac citric acid monohydrate croscarmellose sodium disodium edetate dihydrate artificial guarana flavour 51880/a artificial sweetner flavour 284 glycerol microcrystalline cellulose polysorbate 80 sodium benzoate sorbitol sucrose xanthan gum

New Zealand - English - Medsafe (Medicines Safety Authority)

wyeth consumer healthcare a division of wyeth (nz) limited - aluminium hydroxide 61.2 mg/ml; magnesium hydroxide 19.5 mg/ml - oral suspension - active: aluminium hydroxide 61.2 mg/ml magnesium hydroxide 19.5 mg/ml

New Zealand - English - Medsafe (Medicines Safety Authority)

wyeth consumer healthcare a division of wyeth (nz) limited - aluminium hydroxide 28.1 mg/ml (added as 5.5ml/10ml simeco base cont. 4.9% al203); magnesium hydroxide (11.06mg/ml mgo hydrated to form hydroxide); simeticone 5 mg/ml (added as simethicone emulsion 30%);   - oral suspension - active: aluminium hydroxide 28.1 mg/ml (added as 5.5ml/10ml simeco base cont. 4.9% al203) magnesium hydroxide (11.06mg/ml mgo hydrated to form hydroxide) simeticone 5 mg/ml (added as simethicone emulsion 30%)   excipient: ethanol lemon-mint methyl hydroxybenzoate methylcellulose propyl hydroxybenzoate saccharin sodium sorbitol water

New Zealand - English - Medsafe (Medicines Safety Authority)

wyeth consumer healthcare a division of wyeth (nz) limited - aspirin 325mg; caffeine 15mg; sodium laurilsulfate - soluble tablet - 325mg/15mg - active: aspirin 325mg caffeine 15mg sodium laurilsulfate excipient: chalk citric acid monohydrate maize starch purified talc saccharin sodium

New Zealand - English - Medsafe (Medicines Safety Authority)

wyeth consumer healthcare a division of wyeth (nz) limited - aspirin 398mg; caffeine 22.7mg - tablet - 398mg/22.7mg - active: aspirin 398mg caffeine 22.7mg excipient: starch

New Zealand - English - Medsafe (Medicines Safety Authority)

wyeth consumer healthcare a division of wyeth (nz) limited - glacial acetic acid 17.3 mg/ml; isopropyl alcohol 634 mg/ml - ear drops - active: glacial acetic acid 17.3 mg/ml isopropyl alcohol 634 mg/ml

New Zealand - English - Medsafe (Medicines Safety Authority)

wyeth consumer healthcare a division of wyeth (nz) limited - calcium carbonate 522mg; magnesium carbonate 68mg; sodium bicarbonate 64mg - chewable tablet - active: calcium carbonate 522mg magnesium carbonate 68mg sodium bicarbonate 64mg excipient: calcium stearate maize starch peppermint oil saccharin sodium sucrose